CPP-115

Last updated
CPP-115
CPP-115.svg
Legal status
Legal status
  • Investigational
Identifiers
  • (1S,3S)-3-Amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C7H9F2NO2
Molar mass 177.151 g·mol−1
3D model (JSmol)
  • C1[C@H](CC(=C(F)F)[C@H]1N)C(=O)O
  • InChI=1S/C7H9F2NO2/c8-6(9)4-1-3(7(11)12)2-5(4)10/h3,5H,1-2,10H2,(H,11,12)/t3-,5-/m0/s1
  • Key:CBSRETZPFOBWNG-UCORVYFPSA-N

CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction, [1] infantile spasms, [2] [3] and Tourette syndrome. [4]

CPP-115 is a GABA aminotransferase (GABA-AT) inactivator. [1]

History

CPP-115 was discovered in the research laboratory of Richard B. Silverman, for which he received the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances. [5] It was licensed to Catalyst Pharmaceuticals for development in 2009. [6] [7]

CPP-115 has been granted orphan drug status for the treatment of infantile spasms by the FDA and for the treatment of West syndrome by the European Commission. [8]

As of 2022, CPP-115 is in Phase II clinical trials for Tourette syndrome. [4]

References

  1. 1 2 Pan Y, Gerasimov MR, Kvist T, Wellendorph P, Madsen KK, Pera E, et al. (January 2012). "(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction". Journal of Medicinal Chemistry. 55 (1): 357–366. doi:10.1021/jm201231w. PMC   3257419 . PMID   22128851.
  2. ↑ "Epilepsy Pipeline Tracker: CPP-115". epilepsy.com.
  3. ↑ Doumlele K, Conway E, Hedlund J, Tolete P, Devinsky O (2016). "A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms". Epilepsy & Behavior Case Reports. 6: 67–69. doi:10.1016/j.ebcr.2016.08.002. PMC   5024311 . PMID   27668180.
  4. 1 2 "CPP-115". Adis Insight.
  5. ↑ Silverman RB (January 2012). "The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms". Journal of Medicinal Chemistry. 55 (2): 567–575. doi:10.1021/jm201650r. PMC   3266980 . PMID   22168767.
  6. ↑ Hawker DD, Silverman RB (October 2012). "Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase". Bioorganic & Medicinal Chemistry. 20 (19): 5763–5773. doi:10.1016/j.bmc.2012.08.009. PMC   3448830 . PMID   22944334.
  7. ↑ Bandell B (August 31, 2009). "Catalyst Pharmaceutical signs licensing deal with Northwestern". South Florida Business Journal.
  8. ↑ "Catalyst Pharmaceuticals Expands Commercial Leadership Team" (Press release). Catalyst Pharmaceuticals.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.